Welcome to the e-CCO Library!

P491: In patients with active ulcerative colitis, cytapheresis spares corticosteroids, and reduces hospitalisation time: therapeutic outcomes in 181 consecutive patients.
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

O. Nomura*, T. Osada, T. Shibuya, D. Ishikawa, K. Haga, N. Sakamoto, S. Watanabe

Created: Friday, 22 February 2019, 9:49 AM
P491: Infectious risk of vedolizumab compared with other biological agents in the treatment of Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Innocenti, T.(1,2);Roselli, J.(1,2);Lynch, E.N.(1,2);Apolito, P.(1,2);Parisio, L.(1,2);Bagnoli, S.(2);Macrì, G.(2);Rogai, F.(2);Milani, S.(1);Galli, A.(1);Milla, M.(2);Dragoni, G.(1,2,3);
Created: Wednesday, 2 June 2021, 4:12 PM
P491: INSPIRE: design and implementation aspects of a registry of complex perianal fistulas in Crohn’s disease patients treated with darvadstrocel
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

O. Zmora*1, J. Panés2, C. Drohan3, J. M. Khalid4, S. Campbell-Hill4, C. Agboton5

Created: Friday, 22 February 2019, 9:41 AM
P492 Use of bowel ultrasound to assess disease activity in Crohn’s disease patients after induction therapy with infliximab
Year: 2020
Source:

ECCO'20 Vienna

Authors:

C. Frias Gomes1, C. Neto Nascimento1, F. Pereira2, A. Caldeira2, R. Sousa2, C. Arieira3, S. Xavier3, S. Monteiro3, F. Dias de Castro3, S. Leite3, J. Cotter3, A.A. Santos1, M. Cravo1, J. Torres1, C. Palmela1

Created: Thursday, 30 January 2020, 10:12 AM
P492: A comparison of treatment effects for clinical, endoscopic and histological remission in ulcerative colitis clinical trials
Year: 2022
Source: ECCO'22
Authors: Sedano, R.(1);Hogan, M.(2);Zou, G.(3);Narula, N.(4);Singh, S.(5);Ma, C.(6);Jairath, V.(7);
Created: Friday, 11 February 2022, 3:56 PM
P492: Cumulative safety signal review confirmed the established safety profile of Asacol™ (mesalazine)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Timeus S.*1, Marchi P.2

Created: Wednesday, 20 February 2019, 10:36 AM
P492: Gender differences in patient’s perspectives for impact of inflammatory bowel disease on their life: An Online Korean Association for the Study of Intestinal Disease (KASID) survey
Year: 2018
Source: ECCO '18 Vienna
Authors:

Y.S. Kim1*, G.S. Seo2, S.W. Hwang3, H.J. Yang4, C.H. Tae5, H.J. Lee6, D.-w.L. Lee7, Y.J. Lee8, D.-S. Myung9, J.M. Lee10, Y.T. Jeen11

Created: Thursday, 21 February 2019, 9:14 AM
P492: Influence of the interval of time between the first and the second anti-TNF in the response to treatment in patients with inflammatory bowel disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

I. Baston*1, N. Mora-Cuadrado2, C. Calviño1, V. Mauriz-Barreiro1, D. De la Iglesia1, J. Gonzalez3, R. Ferreiro-Iglesias1, J. E. Dominguez-Munoz1, M. Barreiro-de Acosta1

Created: Friday, 22 February 2019, 9:41 AM
P492: Perioperative complications have long-term effect on quality of life after restorative proctocolectomy
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

Y. Lee1, A. McCombie*1, 2, R. Vanamala1, R. Gearry3, F. Frizelle1, E. McKay1, J. Williman4, T. Eglinton1

Created: Friday, 22 February 2019, 9:49 AM
P492: Subcutaneous infliximab (CT-P13 SC) as maintenance therapy for ulcerative colitis: A Phase 3, randomized, placebo-controlled study: Results of the LIBERTY-UC study
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Sands, B.E.(1)*;Hanauer, S.B.(2);Colombel, J.F.(3);Sandborn, W.(4);Schreiber, S.(5);Danese, S.(6);Klopocka, M.(7);Kulynych, R.(8);Kierkus, J.(9);Soltysiak, A.(10);Smolinski, P.(11);Gonciarz, M.(12);Sreckovic, S.(13);Valuyskikh, E.(14);Horynski, M.(15);Gasbarrini, A.(16);Kim, S.(17);Bae, Y.(17);Lee, S.(17);Lee, J.H.(17);Lee, J.(17);Lee, S.J.(18);Lee, S.G.(18);Kim, J.M.(18);
Created: Friday, 14 July 2023, 11:05 AM
P492: The UC Diet and Antibiotics for Treatment of Mild to Moderate Pediatric Ulcerative Colitis: A prospective open label pilot study
Year: 2021
Source: ECCO'21 Virtual
Authors: Sarbagili Shabat, C.(1,2);Albenberg, L.(3);Van Limbergen, J.(4,5);Otley, A.(6);Yaakov, M.(1);Wine, E.(7);Weiner, D.(1);Levine, A.(1,2);
Created: Wednesday, 2 June 2021, 4:12 PM
P493 Segmental colectomy vs. extended colectomy for colonic Crohn’s disease: results from 112 consecutive patients
Year: 2020
Source:

ECCO'20 Vienna

Authors:

A. Frontali1, A. Chierici1, X. Treton2, L. Maggiori1, Y. Bouhnik2, Y. Panis3

Created: Thursday, 30 January 2020, 10:12 AM
P493: Comparison of the efficacy of infliximab biosimilar (Remsima®) vs. infliximab original (Remicade®) in patients with inflammatory bowel disease
Year: 2018
Source: ECCO '18 Vienna
Authors:

M.F. Guerra Veloz1*, M. Belvis Jimenez1, T. Valdes Delgado1, R. Perea Amarillo1, L. Castro Laria1, B. Maldonado Pérez1, V. Merino2, A. Benítez Roldán1, A. Caunedo Álvarez1, F. Argüelles-Arias1

Created: Thursday, 21 February 2019, 9:14 AM
P493: Cost-effectiveness of venous thromboembolism prophylaxis after hospitalization in patients with Inflammatory Bowel Disease
Year: 2021
Source: ECCO'21 Virtual
Authors: Lee, K.(1);Lim, F.(2);Colombel, J.F.(3);Hur, C.(2);Faye, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P493: Efficacy of anti-TNF for internal fistula in Crohn's disease – results from a retrospective multicenter cohort study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Kobayashi T.*1, Hishida A.2, Tanaka H.3, Bamba S.4, Yamada A.5, Toshimitsu F.6, Shinichiro S.7, Kamata N.8, Yoshino T.9, Hibi T.1 AIM Jr. Internal Fistula Study Group

Created: Wednesday, 20 February 2019, 10:36 AM
P493: Inflammatory sticturing Crohn’s diseases: results of medical treatment
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

N. Bellil1, N. Bibani1, M. Sabbah1, D. Trad1, H. Elloumi1, A. Ouakaa*1, D. Gargouri1

Created: Friday, 22 February 2019, 9:41 AM
P493: Prevalence and risk factors for postoperative septic complications in Crohn’s disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

M. Guasch1, 2, A. Clos1, M. Manyosa3, T. Lobatón3, J. R. Gómez2, M. Piñol4, E. Cabré3, J. Troya4, E. Domènech*3

Created: Friday, 22 February 2019, 9:49 AM
P493: QUASAR Induction Study 1 Cumulative Response to Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Peyrin-Biroulet, L.(1)*;Rubin, D.(2);Lichtenstein, G.(3);Shipitofsky, N.(4);Huang, K.H.(4);Germinaro, M.(4);Wilson, R.(5);Zhang, H.(5);DuVall, G.A.(6);Cao, Q.(7);Allegretti, J.(8);Feagan, B.(9);Hisamatsu, T.(10);Panés, J.(11);Dignass, A.(12);Bressler, B.(13);Sands, B.(14);
Created: Friday, 14 July 2023, 11:05 AM
P493: The synthetic glycan KB295 optimises microbiome composition and function in ulcerative colitis: Results from a proof of principle human study
Year: 2022
Source: ECCO'22
Authors: Meisner, J.(1);Miller , K.(1);Lee, J.(2);Jose, A.(2);Giuggio, M.(3);McComb , M.(1);Humphries, E.(3);Rosini, M.(4);Wingertzahn, M.(5);Shanahan, F.(6);E.T. van Hylckama Vlieg, J.(7);Dowling , M.(1);
Created: Friday, 11 February 2022, 3:56 PM
P494 The efficacy and safety of adalimumab for patients with moderately to severely active ulcerative colitis and predictors of response in Korea
Year: 2020
Source:

ECCO'20 Vienna

Authors:

S. Shin Shin1, S.J. Park2, Y. Kim1, J.P. Im3, H.J. Kim4, K.M. Lee5, J.W. Kim6, S.A. Jung7, J. Lee8, S.B. Kang9, S.J. Shin10, E.S. Kim11, Y.S. Kim12, T.O. Kim13, H.S. Kim14, D.I. Park15, H.K. Kim16, E.S. Kim17, Y.H. Kim18, D.H. Kim19, D. Teng20, J.H. Kim1, W.Y. Kim1, C.H. Choi1

Created: Thursday, 30 January 2020, 10:12 AM